Pharmacokinetics of toremifene.

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Pharmacokinetics

Background:

• Understanding toremifene's absorption, distribution, metabolism, and excretion (ADME) is crucial for optimizing its therapeutic use.
• Previous studies have indicated toremifene's potential in various clinical applications, necessitating detailed pharmacokinetic profiling.

Purpose of the Study:

• To characterize the pharmacokinetics of toremifene in humans following single and multiple oral administrations.
• To determine key pharmacokinetic parameters including absorption, distribution, elimination half-life, and metabolic pathways.

Main Methods:

• Single and multiple oral dose administration of toremifene in human subjects.
• Serum concentration monitoring over time to determine pharmacokinetic parameters.
• Identification and quantification of major toremifene metabolites in serum.

Main Results:

• Toremifene demonstrated complete oral absorption with no first-pass metabolism and achieved peak serum concentrations within 4 hours.
• Linear pharmacokinetics were observed within the 10-680 mg dose range, with distribution and elimination half-lives of 4 hours and 5 days, respectively.
• Toremifene is highly protein-bound (>99%) and extensively metabolized, primarily to demethyl- and deaminohydroxytoremifene, with steady-state levels of 0.8 µg/mL at 60 mg/day.

Conclusions:

• Toremifene exhibits predictable and linear pharmacokinetic behavior in humans after oral administration.
• The identified metabolites, demethyl- and deaminohydroxytoremifene, are significant and their levels vary relative to the parent drug.
• These pharmacokinetic findings provide a foundation for effective dosing strategies and further clinical investigation of toremifene.